Endothelium-Derived Dopamine and 6-Nitrodopamine in the Cardiovascular System
Overview
Authors
Affiliations
The review deals with the release of endothelium-derived dopamine and 6-nitrodopamine (6-ND) and its effects on isolated vascular tissues and isolated hearts. Basal release of both dopamine and 6-ND is present in human isolated umbilical cord vessels, human popliteal vessels, nonhuman primate vessels, and reptilia aortas. The 6-ND basal release was significantly reduced when the tissues were treated with -nitro-l-arginine methyl ester and virtually abolished when the endothelium was mechanically removed. 6-Nitrodopamine is a potent vasodilator, and the mechanism of action responsible for this effect is the antagonism of dopamine D-like receptors. As a vasodilator, 6-ND constitutes a novel mechanism by which nitric oxide modulates vascular tone. The basal release of 6-ND was substantially decreased in endothelial nitric oxide synthase knockout (eNOS) mice and not altered in neuronal nitric oxide synthase knockout (nNOS) mice, indicating a nonneurogenic source for 6-ND in the heart. Indeed, in rat isolated right atrium, the release of 6-ND was not affected when the atria were treated with tetrodotoxin. In the rat isolated right atrium, 6-ND is the most potent endogenous positive chronotropic agent, and in Langendorff's heart preparation, it is the most potent endogenous positive inotropic agent. The positive chronotropic and inotropic effects of 6-ND are antagonized by β-adrenoceptor antagonists at concentrations that do not affect the effects induced by noradrenaline, adrenaline, and dopamine, indicating that blockade of the 6-ND receptor is the major modulator of heart chronotropism and inotropism. The review proposes that endothelium-derived catecholamines may constitute a major mechanism for control of vascular tone and heart functions, in contrast to the overrated role attributed to the autonomic nervous system.
Guazzelli P, Britto-Junior J, Godoy P, Cedano Godoy P Souza P, Cardoso V, Lima A Vasc Biol. 2025; 7(1).
PMID: 39908355 PMC: 11883861. DOI: 10.1530/VB-24-0010.
Santos E, Britto-Junior J, Ribeiro J, Junior G, Lima A, Moraes M Front Pharmacol. 2024; 15:1507802.
PMID: 39640490 PMC: 11619277. DOI: 10.3389/fphar.2024.1507802.
Oliveira D, Cardoso V, Britto-Junior J, Fuguhara V, Frecentese F, Sparaco R Naunyn Schmiedebergs Arch Pharmacol. 2024; .
PMID: 39382679 DOI: 10.1007/s00210-024-03463-3.
Pozzo C, Junior J, Britto-Junior J, Badin J, Barbosa de Souza V, Schenka A Pflugers Arch. 2024; 476(8):1263-1277.
PMID: 38963545 DOI: 10.1007/s00424-024-02985-2.
Britto-Junior J, Furlaneto R, Lima A, de Oliveira M, Severino B, Frecentese F Front Pharmacol. 2024; 15:1348876.
PMID: 38645555 PMC: 11026650. DOI: 10.3389/fphar.2024.1348876.